Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

IVY Network Collaborators

doi:10.1093/cid/ciac439

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

IVY Network Collaborators

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use. Methods . In a multicenter case-control analysis of US adults (≥18 years) hospitalized 11 March to 15 December 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression. Results . After excluding patients receiving mRNA vaccines, among 3979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% confidence interval [CI]: 63-75%) overall, including 55% (29-72%) among immunocompromised patients, and 72% (64-77%) among immunocompetent patients, for whom VEs was similar at 14-90 days (73% [59-82%]), 91-180 days (71% [60-80%]), and 181-274 days (70% [54-81%]) postvaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18-65%) among immunocompetent patients. Conclusions . The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months postvaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.

Original language	English (US)
Pages (from-to)	S159-S166
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	75
Issue number	2
DOIs	https://doi.org/10.1093/cid/ciac439
State	Published - Oct 3 2022
Externally published	Yes

Keywords

COVID-19
vaccine effectiveness
viral vector vaccines

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciac439

Cite this

IVY Network Collaborators (2022). Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75(2), S159-S166. https://doi.org/10.1093/cid/ciac439

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. / IVY Network Collaborators.

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 75, No. 2, 03.10.2022, p. S159-S166.

Research output: Contribution to journal › Article › peer-review

IVY Network Collaborators 2022, 'Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 75, no. 2, pp. S159-S166. https://doi.org/10.1093/cid/ciac439

IVY Network Collaborators. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 Oct 3;75(2):S159-S166. doi: 10.1093/cid/ciac439

IVY Network Collaborators. / Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 ; Vol. 75, No. 2. pp. S159-S166.

@article{4bb489b647a7454c8146fecff62fc2da,

title = "Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States",

abstract = "Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use. Methods . In a multicenter case-control analysis of US adults (≥18 years) hospitalized 11 March to 15 December 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression. Results . After excluding patients receiving mRNA vaccines, among 3979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% confidence interval [CI]: 63-75%) overall, including 55% (29-72%) among immunocompromised patients, and 72% (64-77%) among immunocompetent patients, for whom VEs was similar at 14-90 days (73% [59-82%]), 91-180 days (71% [60-80%]), and 181-274 days (70% [54-81%]) postvaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18-65%) among immunocompetent patients. Conclusions . The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months postvaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.",

keywords = "COVID-19, vaccine effectiveness, viral vector vaccines",

author = "{IVY Network Collaborators} and Lewis, {Nathaniel M.} and Self, {Wesley H.} and Manjusha Gaglani and Ginde, {Adit A.} and Douin, {David J.} and {Keipp Talbot}, H. and Casey, {Jonathan D.} and Mohr, {Nicholas M.} and Anne Zepeski and Ghamande, {Shekhar A.} and McNeal, {Tresa A.} and Shapiro, {Nathan I.} and Gibbs, {Kevin W.} and Files, {D. Clark} and Hager, {David N.} and Arber Shehu and Prekker, {Matthew E.} and Erickson, {Heidi L.} and Gong, {Michelle N.} and Amira Mohamed and Johnson, {Nicholas J.} and Vasisht Srinivasan and Steingrub, {Jay S.} and Peltan, {Ithan D.} and Brown, {Samuel M.} and Martin, {Emily T.} and Monto, {Arnold S.} and Akram Khan and Busse, {Laurence W.} and Lohuis, {Caitlin C.Ten} and Abhijit Duggal and Wilson, {Jennifer G.} and Gordon, {Alexandra June} and Nida Qadir and Chang, {Steven Y.} and Christopher Mallow and Carolina Rivas and Babcock, {Hilary M.} and Kwon, {Jennie H.} and Exline, {Matthew C.} and Lauring, {Adam S.} and Natasha Halasa and Chappell, {James D.} and Grijalva, {Carlos G.} and Rice, {Todd W.} and Rhoads, {Jillian P.} and Jones, {Ian D.} and Stubblefield, {William B.} and Adrienne Baughman and Womack, {Kelsey N.}",

note = "Publisher Copyright: Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022.",

year = "2022",

month = oct,

day = "3",

doi = "10.1093/cid/ciac439",

language = "English (US)",

volume = "75",

pages = "S159--S166",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

AU - IVY Network Collaborators

AU - Lewis, Nathaniel M.

AU - Self, Wesley H.

AU - Gaglani, Manjusha

AU - Ginde, Adit A.

AU - Douin, David J.

AU - Keipp Talbot, H.

AU - Casey, Jonathan D.

AU - Mohr, Nicholas M.

AU - Zepeski, Anne

AU - Ghamande, Shekhar A.

AU - McNeal, Tresa A.

AU - Shapiro, Nathan I.

AU - Gibbs, Kevin W.

AU - Files, D. Clark

AU - Hager, David N.

AU - Shehu, Arber

AU - Prekker, Matthew E.

AU - Erickson, Heidi L.

AU - Gong, Michelle N.

AU - Mohamed, Amira

AU - Johnson, Nicholas J.

AU - Srinivasan, Vasisht

AU - Steingrub, Jay S.

AU - Peltan, Ithan D.

AU - Brown, Samuel M.

AU - Martin, Emily T.

AU - Monto, Arnold S.

AU - Khan, Akram

AU - Busse, Laurence W.

AU - Lohuis, Caitlin C.Ten

AU - Duggal, Abhijit

AU - Wilson, Jennifer G.

AU - Gordon, Alexandra June

AU - Qadir, Nida

AU - Chang, Steven Y.

AU - Mallow, Christopher

AU - Rivas, Carolina

AU - Babcock, Hilary M.

AU - Kwon, Jennie H.

AU - Exline, Matthew C.

AU - Lauring, Adam S.

AU - Halasa, Natasha

AU - Chappell, James D.

AU - Grijalva, Carlos G.

AU - Rice, Todd W.

AU - Rhoads, Jillian P.

AU - Jones, Ian D.

AU - Stubblefield, William B.

AU - Baughman, Adrienne

AU - Womack, Kelsey N.

N1 - Publisher Copyright: Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022.

PY - 2022/10/3

Y1 - 2022/10/3

N2 - Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use. Methods . In a multicenter case-control analysis of US adults (≥18 years) hospitalized 11 March to 15 December 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression. Results . After excluding patients receiving mRNA vaccines, among 3979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% confidence interval [CI]: 63-75%) overall, including 55% (29-72%) among immunocompromised patients, and 72% (64-77%) among immunocompetent patients, for whom VEs was similar at 14-90 days (73% [59-82%]), 91-180 days (71% [60-80%]), and 181-274 days (70% [54-81%]) postvaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18-65%) among immunocompetent patients. Conclusions . The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months postvaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.

AB - Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use. Methods . In a multicenter case-control analysis of US adults (≥18 years) hospitalized 11 March to 15 December 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression. Results . After excluding patients receiving mRNA vaccines, among 3979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% confidence interval [CI]: 63-75%) overall, including 55% (29-72%) among immunocompromised patients, and 72% (64-77%) among immunocompetent patients, for whom VEs was similar at 14-90 days (73% [59-82%]), 91-180 days (71% [60-80%]), and 181-274 days (70% [54-81%]) postvaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18-65%) among immunocompetent patients. Conclusions . The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months postvaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.

KW - COVID-19

KW - vaccine effectiveness

KW - viral vector vaccines

UR - http://www.scopus.com/inward/record.url?scp=85135943048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135943048&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac439

DO - 10.1093/cid/ciac439

M3 - Article

C2 - 35675695

AN - SCOPUS:85135943048

SN - 1058-4838

VL - 75

SP - S159-S166

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this